By CERBIOS-PHARMA SA
To get in touch with CERBIOS-PHARMA SA, simply fill out the form below.
Subscribe to Supplier
Cerbios-Pharma debuts as face-to-face presence at 11th Anniversary HPAPI Summit Boston
Lugano, Switzerland: – Active Pharmaceutical Ingredients specialist Cerbios-Pharma SA (Cerbios) will make its live debut as Exhibition Partner at the 11th Annual HPAPI Summit, to be held in Boston in late June 2022, after attending with a virtual booth at last years’ online event.
At the reconvened physical summit in Boston, Cerbios will be present with its own booth, to be staffed by M&S Manager for Pharma & CDMO Valentino Mandelli who will present the company’s flagship CDMO service portfolio focused on highly potent APIs (HPAPIs) and antibody-drug conjugates (ADCs).
Cerbios actively manufactures since long many different classes of HPAPIs, including COPDs, Vitamin D derivatives, payloads for ADCs and more.
Currently, Cerbios has five units dedicated to HPAPIs that are fully isolated to meet SafeBridge® high containment standards up to Category 4.
Cerbios, recently named as TOP European CDMO of the Year by a pool of expert from Pharmatech Outlook, is also a leading player in the CDMO arena for ADCs, where offers end-to-end solutions thanks to its PROVEO division.
Cerbios is a privately held company located in Lugano, Switzerland, specialized in manufacturing Pharma Products and in offering CDMO services.
Cerbios is the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Proveo (TM) is a Cerbios division recently created to provide end-to-end development and manufacturing services for ADCs.
Cerbios is also a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders. Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response.
Learn more at: https://cerbios.swiss
About HPAPI Summit 2022
First staged in 2011, the HPAPI Summit is dedicated to knowledge sharing and best practice in the challenges of safe handling High Potency Active Pharmaceutical Ingredients (HPAPIs), covering the latest containment, industrial hygiene, EHS (Environmental Health & Safety) challenges and outsourcing developments.
The 11th Annual HPAPI Summit returns to being a three-day face-to-face event, opening June 28 at the Hyatt Regency Boston.
Themed ‘De-Risking Highly Potent APIs & Hazardous New Modalities’, the 2022 summit will explore the new post-pandemic modalities now dominating pharma and biotech pipelines, including tightening regulations on impurities, and supply chain challenges to single use manufacturing. The conference will offer end-to-end coverage on all aspects of potent & cytotoxic drug production, across small molecules, biologics, ATMPs & drug conjugates.
The event is organised by Hanson Wade with further details at: http://hpapi-summit.com